Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Quit Smoking Drugs Market Revenue Growth Supported By A CAGR Of 90.72% Through 2030
The market for smoking cessation medications has experienced rapid expansion in recent years, with its size projected to increase from $44.23 billion in 2025 to $50.94 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.2%. Key factors driving this historical growth include heightened public awareness of the dangers associated with smoking, a growing incidence of health conditions linked to smoking, the widespread availability of nicotine replacement options, ongoing government initiatives to curb tobacco use, and the expansion of pharmaceutical production in developing economies.
The market for smoking cessation drugs is projected to experience rapid expansion in the coming years, reaching a value of $90.73 billion by 2030 with a compound annual growth rate (CAGR) of 15.5%. This growth during the forecast period is driven by progress in digital health solutions, the increasing use of personalized medicine, the incorporation of artificial intelligence into treatment tracking, the broadening of telemedicine services, and the rise of wearable health monitoring devices. Key trends expected to shape this period include customized nicotine replacement therapies, mobile health (mHealth) and smoking cessation applications, telemedicine-based prescription assistance, the combination of behavioral therapy with drug treatments, and wearable devices designed to track cravings.
Download A Free Sample Report For Comprehensive Market Insights:
Quit Smoking Drugs Market Opportunity Drivers: What Is Creating New Revenue Potential?
The upward trend in smoking addiction rates is anticipated to fuel expansion in the quit-smoking drug market in the coming period. Smoking involves the act of drawing in and releasing vapors from burnt organic materials like tobacco, cannabis, hashish, and other substances. Medications designed to assist smoking cessation work by diminishing the desire to smoke through curbing tobacco cravings in individuals, serving as prescription remedies to manage nicotine withdrawal symptoms for effective quitting. As an illustration, data from the OECD, an intergovernmental entity based in France, revealed in November 2025 that 14.8% of adults aged 15 and above were daily smokers in 2023. This habit was most prevalent in Türkiye, Hungary, Greece, and among accession or partner nations such as Indonesia, Bulgaria, and China, where at least a quarter of the population engaged in daily smoking. On average, daily smoking was reported by 18.5% of men versus 11.4% of women during the same period. Consequently, the escalating incidence of smoking addiction is fueling growth within the quit-smoking drug market.
Quit Smoking Drugs Market Segment Breakdown: Which Categories Generate The Most Revenue?
The quit smoking drugs market covered in this report is segmented –
1) By Product: Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, Nicotine Sublingual Tablets
2) By Drug: Varenicline (Chantix), Bupropion (Zyban), Other Drugs
3) By Distribution: Drug Store, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Drug Therapy: Bupropion (Zyban), Varenicline (Chantix)
2) By E-Cigarettes: Disposable E-Cigarettes, Rechargeable E-Cigarettes, Pod Systems
3) By Nicotine Inhalers: Prescription Inhalers, Over-The-Counter Inhalers
4) By Nicotine Replacement Therapies (NRT): Nicotine Patches, Nicotine Gum, Nicotine Lozenges
5) By Nicotine Sublingual Tablets: Fast-Acting Sublingual Tablets, Extended-Release Sublingual Tablets
Quit Smoking Drugs Market Innovation Trends Driving Future Development
Major companies in the quit smoking drugs market are concentrating on creating novel formulations and delivery methods, including generic tablets, to strengthen their market presence across different regions and achieve a competitive advantage. These generic varenicline tablets are unbranded versions of the drug containing varenicline tartrate, which are bioequivalent to the original branded product and designed for smoking cessation therapy. For example, in January 2024, Lupin Limited, a pharmaceutical firm based in India, introduced new Varenicline tablets in the United States, offered in 0.5 mg and 1 mg strengths. These tablets represent the generic equivalents of Chantix tablets (0.5 mg and 1 mg) from PF Prism C.V. and are used to aid in smoking cessation treatment. Acting as a partial agonist at the nicotinic acetylcholine receptor, varenicline facilitates dopamine release, helping to ease withdrawal symptoms and cravings linked to nicotine addiction. Through this dual action, it lessens the enjoyable aspects of smoking while offering some stimulation to mitigate withdrawal effects.
Quit Smoking Drugs Market Key Players And Strategic Industry Positioning
Major companies operating in the quit smoking drugs market are 22nd Century Group, Cipla Limited, Dr. Reddy’s Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, BioCorRx Inc., Ennaid Therapeutics LLC, Fertin Pharma A/S, Hikma Pharmaceuticals PLC, IntelGenx Technologies Corp., Innovus Pharmaceuticals Inc., Gilla Inc., Rusan Pharma Ltd., Novartis AG
Access The Complete Quit Smoking Drugs Market Report:
Quit Smoking Drugs Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the quit smoking drugs market in 2025. The regions covered in the quit smoking drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model